Sign In
Buy HOWL
$0.362
-0.0084 (-2.27%)
At Close: Jun 23, 2026
Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates
04:05pm, Thursday, 07'th May 2026
WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
07:00am, Friday, 27'th Mar 2026
Company continues to evaluate strategic options to maximize shareholder value Company continues to evaluate strategic options to maximize shareholder value
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives
04:09pm, Tuesday, 24'th Feb 2026
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development
Analysts Set Werewolf Therapeutics, Inc. (NASDAQ:HOWL) PT at $3.75
01:57am, Friday, 20'th Feb 2026
Shares of Werewolf Therapeutics, Inc. (NASDAQ: HOWL - Get Free Report) have earned a consensus recommendation of "Hold" from the seven research firms that are presently covering the firm, Marketbeat r
Luke Evnin Sells 24,678 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock
05:20am, Wednesday, 14'th Jan 2026
Werewolf Therapeutics, Inc. (NASDAQ: HOWL - Get Free Report) Director Luke Evnin sold 24,678 shares of the firm's stock in a transaction that occurred on Friday, January 9th. The shares were sold at a
Luke Evnin Sells 24,962 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock
05:22am, Sunday, 04'th Jan 2026
Werewolf Therapeutics, Inc. (NASDAQ: HOWL - Get Free Report) Director Luke Evnin sold 24,962 shares of the company's stock in a transaction that occurred on Wednesday, December 31st. The stock was sol
Luke Evnin Sells 18,568 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock
05:22am, Sunday, 04'th Jan 2026
Werewolf Therapeutics, Inc. (NASDAQ: HOWL - Get Free Report) Director Luke Evnin sold 18,568 shares of Werewolf Therapeutics stock in a transaction that occurred on Friday, January 2nd. The shares wer
Werewolf Therapeutics Announces Pipeline and Business Updates
08:00am, Thursday, 18'th Dec 2025
WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of post-ICI advanced or metastatic cutaneous melanoma patients, with potential best-in
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
01:01pm, Monday, 15'th Dec 2025
Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Novel INDUCER™ T Cell Engager Platform designed to mitigate systemic toxicities Sequential dosing of INDUKINE™ molecules in preclinical model showed potent antitumor activity with improved safety
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
07:00am, Tuesday, 04'th Nov 2025
– Update on WTX-124 Phase 1/1b clinical trial interim data and End of Phase 1 meeting with the U.S. Food & Drug Administration (FDA) is expected to be provided later in the fourth quarter of 2025 �
Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why
01:01pm, Thursday, 23'rd Oct 2025
Werewolf Therapeutics (HOWL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
08:00am, Wednesday, 08'th Oct 2025
Fast Track Designation underscores the promise of Werewolf's INDUKINE™ platform WATERTOWN, Mass., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting
09:00am, Friday, 03'rd Oct 2025
WATERTOWN, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development
Werewolf Therapeutics, Inc. (HOWL) Just Flashed Golden Cross Signal: Do You Buy?
06:06pm, Monday, 08'th Sep 2025
Werewolf Therapeutics, Inc. (HOWL) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, HOWL's 50-day simple moving average crosse
